Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT02038127
Recruiting Observational

Gangwon PCI Prospective Registry

NCT02038127 · tracked via the Priya Life Science South Korea tracker
Sponsor
Yonsei University
Phase
Observational
Started
2013-01-01
Last updated
2026-10-07

Condition(s) studied

Coronary Artery DiseaseIschemic Heart Disease (IHD)Unstable Angina (UA)Non-ST Elevated Myocardial InfarctionST-Elevation Myocardial InfarctionVasospastic Angina

Investigational drug(s) / intervention(s)

Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention (PCI): PCI performed as part of routine clinical care; no study-specific procedure is assigned.

Study summary

This prospective, multicenter registry will consecutively enroll patients of all ages undergoing percutaneous coronary intervention (PCI) at four university hospitals in Gangwon Province, Republic of Korea.

The study will describe contemporary clinical, procedural, and medication treatment patterns and assess 1-year clinical outcomes in routine practice.

The primary outcome is patient-oriented composite outcome (POCO), defined as all-cause death, any myocardial infarction, or any repeat revascularization.

No study-specific intervention will be assigned.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of any age undergoing percutaneous coronary intervention (PCI) at a participating hospital during the study period. * Written informed consent is obtained from the patient or a legally authorized representative before collection of study data, unless the requirement for informed consent is waived by the Institutional Review Board. Exclusion Criteria: * Refusal or withdrawal of informed consent, when informed consent is required. * No PCI performed during the index hospital encounter.

Primary outcome measure(s)

  • Patient-oriented composite outcome (POCO) — Within 1 year after the index PCI procedure
    A composite of all-cause death, any myocardial infarction, or any repeat revascularization.

Trial sites (4)

FacilityCityRegionStatus
Chuncheon Hallym University Hospital Chuncheon Gangwon-do Recruiting
Kangwon National University Hospital Chuncheon Gangwon-do Recruiting
Gangneung Asan Hospital Gangneung Gangwon-do Recruiting
Wonju Severance Christian Hospital Wŏnju Gangwon-do Recruiting

More Yonsei University trials in South Korea

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC Recruiting
Aspirin vs Clopidogrel After TAVR Recruiting
Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers Recruiting
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) Recruiting
Home-based Rehabilitation Monitoring System With Wearable Devices and Self-Report Application Active, not recruiting

Other trials for the same condition

Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease Active, not recruiting
The COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique Recruiting
CREATE Trial, Prospective, Observational Study Active, not recruiting
Study of the Natural History of FFR Guided Percutaneous Coronary Intervention Recruiting
Safety and Efficacy of Paclitaxel Coated PTCA Balloon Catheter With a Shellac Plus Vitamin E Excipient (GENOSS® DCB) in Patients With Coronary In-stent Restenosis (ISR): A Prospective, Multi-center, Observational Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02038127 on ClinicalTrials.gov ↗ ← All trials in South Korea